← Library
Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

PNC-27

Not FDA approved

Experimental anticancer peptide

Evidence score
21/ 100
Thin evidence

Very thin human evidence

  • Regulatory standing. Sold as a research chemical, not approved
  • Animal / preclinical only. Evidence is largely animal or in-vitro
  • No registered human trials. Nothing registered on ClinicalTrials.gov
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

PNC-27 is a synthetic research peptide that combines a segment of the p53 protein's MDM2-binding region with a membrane-penetrating sequence. In laboratory studies it is thought to bind HDM-2 (MDM2) proteins found on the membranes of some cancer cells and form pores that lead to cell death, while largely sparing normal cells.

What the evidence shows

Automatic summaryAnimal / preclinical

Evidence comes mainly from cell culture and animal studies, and there are no registered human clinical trials. Any effect against cancer in people has not been established, and safety in humans is unknown.

Key facts

Molecular formula
C188H293N53O44S
Molecular weight
4032 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies
Nonemost advanced phase
0completed (sample)
0recruiting (sample)

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

21papers referencing PNC-27

NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.

Biochemistry2004

Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.

Proc Natl Acad Sci U S A2010

P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells.

Expert Opin Drug Deliv2016

Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.

Leukemia2020

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.